Deutsche Bank raised the firm’s price target on Spyre Therapeutics (SYRE) to $102 from $86 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYRE:
- Spyre Therapeutics price target raised to $97 from $64 at Citi
- Spyre Therapeutics price target raised to $107 from $92 at Stifel
- Julian Harrison Reiterates Buy on Spyre Therapeutics, Maintains $98 Price Target on Strong IBD Pipeline and Cash Runway
- Spyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for Stockholders
- Spyre Therapeutics reports Q1 EPS (74c), consensus (65c)